John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science
Director, Marble Center for Cancer Nanomedicine
Member, Ludwig Center at MIT
Investigator, Howard Hughes Medical Institute
Institute Member, Broad Institute of MIT and Harvard
Associated Faculty, Wyss Institute
Biomedical Engineer, Brigham and Women's Hospital, Department of Medicine
Sangeeta N. Bhatia
Nano-based drugs, Detection & monitoring, Metastasis, Precision medicine, Immunology & immunotherapy
Our laboratory conducts research at the intersection of engineering, medicine, and biology to develop novel platforms for understanding, diagnosing and treating human disease. Our long-term goals are to improve cellular therapies for liver disease and to develop nanotechnology for the diagnosis and treatment of cancer.
The Bhatia Laboratory engineers micro and nanotechnologies, also called “tiny technologies,” to address complex challenges in human health ranging from cancer to liver disease and acquired infections. Operating at the interface of living and synthetic systems, the Bhatia group uses these miniaturization tools to improve areas of medicine including diagnostics, drug delivery, tissue regeneration, and disease modeling. In cancer, Bhatia’s multidisciplinary team develops tools for use in diagnostics and detection, and in precision therapeutics to specifically target tumors. Nanosensors designed by the Bhatia team are capable of detecting and profiling very early-stage tumors, and can be analyzed via a simple urine test. The same technology may also yield insights into a tumor’s response to certain therapies. The Bhatia Lab has also created human microlivers, which model human drug metabolism, liver disease, and interaction with pathogens.
Sangeeta Bhatia earned her BS at Brown University, followed by an MS in mechanical engineering at MIT, a PhD in biomedical engineering at the Harvard-MIT Division of Health Sciences and Technology, and an MD at Harvard Medical School. Prior to her appointment at MIT, Bhatia held a tenured position at UCSD. She and her trainees have launched multiple biotechnology companies to improve human health. As a prolific inventor and passionate advocate for diversity in science and engineering, Bhatia has received many honors including the Lemelson-MIT Prize, known as the “Oscar for inventors,” and the Heinz Medal for groundbreaking inventions and advocacy for women in STEM fields. She is a Howard Hughes Medical Institute Investigator, Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT, and an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine, the American Academy of Arts and Science, the National Academy of Inventors, and Brown University's Board of Fellows. Bhatia is a board member of Brown University, Vertex Pharmaceuticals*, and the Association for Women in Science. She has an advisory role with Chan Zuckerberg Biohub, Global Oncology Inc., Glympse BIO*, CEND Therapeutics*, and Satellite Bio*. She has a consulting role at Moderna Therapeutics and receives sponsored research funding from Johnson & Johnson.
*Dr. Sangeeta Bhatia holds equity in these institutions